{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T06:29:33Z","timestamp":1770704973207,"version":"3.49.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[1997,11,1]],"date-time":"1997-11-01T00:00:00Z","timestamp":878342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,7,27]]},"abstract":"<jats:title>SUMMARY<\/jats:title>\n               <jats:p>Ten CVID patients with defective IL-2 synthesis in vitro were treated with nhuIL-2 in a placebo-controlled, double blind, crossover therapy study during a period of 12 months. No severe side-effects of nhuIL-2 were recorded. Marginal serum nhuIL-2 levels were measurable in individual patients only during the therapy phase. Serum levels of soluble IL-2 receptors were unaffected by the therapy. nhuIL-2 and placebo groups did not differ significantly with respect to requirement of IVIG substitutions which were performed whenever serum IgG levels dropped below 5 g\/l: a total of 53 IVIG infusions (corresponding to 17.6 g IgG\/month per patient) was necessary during the placebo phase, and 48 infusions (16-4 g IgG\/month per patient) during the nhuIL-2 treatment phase. Thus, nhuIL-2 therapy was ineffective in improving spontaneous IgG synthesis in vivo. Nevertheless, the group of patients receiving nhuIL-2 during the first 6 months of the study exhibited a significant reduction of severe infections (n= 25) during the following 6 months of placebo treatment (n = 7) (P&amp;lt; 0\u2013045). The infection score dropped in this group from 181 to 23 (P &amp;lt; 0015). Patients of the second group receiving first placebo and then nhuIL-2 did not experience a significant difference in number and score of infectious episodes: 25 infections were recorded during the first 6 months and 24 during the following 6 months. We suppose that nhuIL-2 therapy of CVID patients reduces susceptibility to severe infections, possibly via the induction of a specific antibody response, which is effective at the earliest 6 months after initiating nhuIL-2 therapy.<\/jats:p>","DOI":"10.1111\/j.1365-2249.1997.tb08313.x","type":"journal-article","created":{"date-parts":[[2010,8,12]],"date-time":"2010-08-12T14:09:16Z","timestamp":1281622156000},"page":"167-173","source":"Crossref","is-referenced-by-count":17,"title":["A double blind, placebo-controlled, crossover therapy study with natural human IL-2 (nhuIL-2) in combination with regular intravenous gammaglobulin (IVIG) infusions in 10 patients with common variable immunodeficiency (CVID)"],"prefix":"10.1093","volume":"110","author":[{"given":"J A","family":"RUMP","sequence":"first","affiliation":[{"name":"Division of Rheumatology and Clinical Immunology, Department of Medicine, University Hospital, Freiburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"JAHREIS","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Clinical Immunology, Department of Medicine, University Hospital, Freiburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"SCHLESIER","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Clinical Immunology, Department of Medicine, University Hospital, Freiburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"STECHER","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Clinical Immunology, Department of Medicine, University Hospital, Freiburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H H","family":"PETER","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Clinical Immunology, Department of Medicine, University Hospital, Freiburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2007,7,27]]},"reference":[{"key":"2022011518425244300_b1","first-page":"195","article-title":"Primary immunodeficiency diseases: report of a WHO Scientific Group","volume":"3","author":"WHO Scientific Group","year":"1992","journal-title":"Immunodefic Rev"},{"key":"2022011518425244300_b2","first-page":"10","article-title":"Primary immunodeficiency diseases","volume":"99","author":"WHO Scientific Group","year":"1995","journal-title":"Clin Exp Immunol"},{"key":"2022011518425244300_b3","first-page":"14","article-title":"Clinical and cellular features of \u2018common variable\u2019 hypogammaglobulinemia","volume":"10","author":"Webster","year":"1990","journal-title":"J Immunol Immunopharmacol"},{"key":"2022011518425244300_b4","doi-asserted-by":"crossref","first-page":"6008","DOI":"10.1073\/pnas.79.19.6008","article-title":"Three distinct B cell defects in common variable immunodeficiency","volume":"79","author":"Saiki","year":"1982","journal-title":"Proc Natl Acad Sci USA"},{"key":"2022011518425244300_b5","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/0091-6749(89)90177-2","article-title":"The failure of B cells in common variable immunodeficiency to transit from proliferation to differentiation is associated with altered B cell surface display","volume":"841","author":"Saxon","year":"1989","journal-title":"J Allergy Clin Immunol"},{"key":"2022011518425244300_b6","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/0090-1229(89)90019-6","article-title":"B cell function in acquired common variable hypogammaglobulinemia: proliverative responses to lymphokines","volume":"51","author":"Farrant","year":"1989","journal-title":"Clin Immunol Immunopathol"},{"key":"2022011518425244300_b7","first-page":"199","article-title":"Cellular abnormalities in common variable immunodeficiency","volume":"2","author":"Spickett","year":"1990","journal-title":"Immunodef Rev"},{"key":"2022011518425244300_b8","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/j.1365-2249.1991.tb05704.x","article-title":"Defects in proliferative responses of T cells from patients with common variable immunodeficiency on direct activation of protein kinase C","volume":"85","author":"North","year":"1991","journal-title":"Clin Exp Immunol"},{"key":"2022011518425244300_b9","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2249.1992.tb05826.x","article-title":"Immunophenotypical alterations in a subset of patients with common variable immunodeficiency (CVID)","volume":"90","author":"Baumert","year":"1992","journal-title":"Clin Exp Immunol"},{"key":"2022011518425244300_b10","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1365-2249.1994.tb06228.x","article-title":"Failure in antigen responses by T cells from patients with common variable immunodeficiency (CVID)","volume":"96","author":"Stagg","year":"1994","journal-title":"Clin Exp Immunol"},{"key":"2022011518425244300_b11","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.1182\/blood.V84.12.4234.bloodjournal84124234","article-title":"A defect in early phase of T-cell receptor-mediated T-cell activation in patients with common variable immunodeficiency","volume":"84","author":"Fischer","year":"1994","journal-title":"Blood"},{"key":"2022011518425244300_b12","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1365-2249.1995.tb02281.x","article-title":"Defects in antigen-driven lymphocyte responses in common variable immunodeficiency (CVID) are due to a reduction in the number of antigen-specific CD4+ T cells","volume":"101","author":"Funauchi","year":"1995","journal-title":"Clin Exp Immunol"},{"key":"2022011518425244300_b13","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/0167-5699(89)90323-X","article-title":"The role of lymphokines in common variable hypogammaglobulinemia","volume":"6","author":"Spickett","year":"1989","journal-title":"Immunol Today"},{"key":"2022011518425244300_b14","first-page":"334","article-title":"Peripheral blood lymphocytes of patients with common variable immunodeficiency (CVID) produce reduced levels of interleukin 4, interleukin 2 and interferon-gamma, but proliferate normally upon activation by mitogens","volume":"78","author":"Pastorelli","year":"1989","journal-title":"Clin Exp Immunol"},{"key":"2022011518425244300_b15","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/0091-6749(93)90178-I","article-title":"Defective interleukin-2 and interferon-\u03b3 gene expression in response to antigen in a subgroup of patients with common variable immunodeficiency","volume":"92","author":"Fischer","year":"1993","journal-title":"J Allergy Clin Immunol"},{"key":"2022011518425244300_b16","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/BF00919383","article-title":"Reduced interleukin-2 (IL-2) production in common variable immunodeficiency is due to a primary abnormality of CD4+ T cell differentiation","volume":"13","author":"Eisenstein","year":"1993","journal-title":"J Clin Immunol"},{"key":"2022011518425244300_b17","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1365-2249.1995.tb03779.x","article-title":"Alterations in interleukin secretion (IL-2 and IL-4) by CD4 and CD4 CD45RO cells from common variable immunodeficiency (CVI) patients","volume":"102","author":"Ferrer","year":"1995","journal-title":"Clin Exp Immunol"},{"key":"2022011518425244300_b18","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1365-3083.1995.tb03556.x","article-title":"Reduced IL-2 expression upon antigen stimulation is accompanied by deficient IL9 gene expression in T cells of patients with CVID","volume":"41","author":"Hauber","year":"1995","journal-title":"Scand J Immunol"},{"key":"2022011518425244300_b19","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/j.1365-2249.1992.tb06933.x","article-title":"Possible role of IL2 deficiency for hypogammaglobulinemia in patients with common variable immunodeficiency","volume":"89","author":"Rump","year":"1992","journal-title":"Clin Exp Immunol"},{"key":"2022011518425244300_b20","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/0140-6736(93)91746-9","article-title":"Interleukin 10 and immune restoration in common variable immunodeficiency","volume":"342","author":"Zielen","year":"1993","journal-title":"Lancet"},{"key":"2022011518425244300_b21","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1046\/j.1365-3083.1997.d01-381.x","article-title":"IL-4 synergizes with IL-10 and anti-CD40 MoAbs to induce B-cell differentiation in patients with common variable immunodeficiency","volume":"45","author":"Punnonen","year":"1997","journal-title":"Scand J Immunol"},{"key":"2022011518425244300_b22","first-page":"17","article-title":"Anti-CD28 enhances defective mitogen responses by mononuclear cells from patients with common variable immunodeficiency","volume":"4","author":"North","year":"1993","journal-title":"Immunodeficiency"},{"key":"2022011518425244300_b23","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/j.1365-2249.1994.tb06511.x","article-title":"Co-stimulation with anti-CD28 (Kolt-2) enhance DNA synthesis by defective T-cells in common variable immunodeficiency","volume":"95","author":"North","year":"1994","journal-title":"Clin Exp Immunol"},{"key":"2022011518425244300_b24","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2249.1994.tb06512.x","article-title":"The costimulatory signal CD28 is fully functional but cannot correct the impaired antigen response in T cells of patients with common variable immunodeficiency","volume":"95","author":"Fischer","year":"1994","journal-title":"Clin Exp Immunol"},{"key":"2022011518425244300_b25","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1159\/000237438","article-title":"Transient CD80 expression defect in a patient with variable immunodeficiency and cyclic neutropenia","volume":"112","author":"Moser","year":"1997","journal-title":"Int Arch Allergy Immunol"},{"key":"2022011518425244300_b26","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1073\/pnas.91.3.1099","article-title":"CD40 ligand expression is defective in a subset of patients with common variable immunodeficiency","volume":"91","author":"Farrington","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"2022011518425244300_b27","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1006\/clin.1994.1155","article-title":"Effect on immunoglobulin production by anti-CD40-activated human B cells: synergistic effect with IL-10 and antagonistic effect with IL-4","volume":"72","author":"Nonoyama","year":"1994","journal-title":"Clin Immunol Immunopathol"},{"key":"2022011518425244300_b28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2249.1997.d01-989.x","article-title":"Antigen presentation by common variable immunodeficiency (CVID) B cells and monocytes is unimpaired","volume":"108","author":"Thon","year":"1997","journal-title":"Clin Exp Immunol"},{"key":"2022011518425244300_b29","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0090-1229(90)90145-G","article-title":"Classification of patients with common variable immuno-deficiency by B cell secretion of IgM and IgG in response to anti-IgM and interleukin-2","volume":"56","author":"Bryant","year":"1990","journal-title":"Clin Immunol Immunopathol"},{"key":"2022011518425244300_b30","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1126\/science.3131876","article-title":"Interleukin-2: inception impact and implications","volume":"240","author":"Smith","year":"1988","journal-title":"Science"},{"key":"2022011518425244300_b31","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/0092-8674(89)90121-9","article-title":"Pleiotropy and redundancy: T cell-derived lymphokines in the immune response","volume":"57","author":"Paul","year":"1989","journal-title":"Cell"},{"key":"2022011518425244300_b32","first-page":"266","volume-title":"Interleukins: molecular biology and immunology","author":"Riegel","year":"1992"},{"key":"2022011518425244300_b33","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1172\/JCI116701","article-title":"Activated B cells from patients with common variable immunodeficiency proliferate and synthesize immunoglobulin","volume":"92","author":"Nonoyama","year":"1993","journal-title":"J Clin Invest"},{"key":"2022011518425244300_b34","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0140-6736(89)91674-7","article-title":"Low dose interleukin 2 induces systemic immune responses against HbsAg in immunodeficient non responders to hepatitis B vaccination","volume":"1","author":"Meuer","year":"1989","journal-title":"Lancet"},{"key":"2022011518425244300_b35","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/0090-1229(92)90058-V","article-title":"Restoration of immunoglobulin secretion in vitro in common variable immunodeficiency by in vivo treatment with polyethylene glycol-conjugated human recombinant interleukin-2","volume":"64","author":"Cunningham-Rundles","year":"1992","journal-title":"Clin Immunol Immunopathol"},{"key":"2022011518425244300_b36","first-page":"31","article-title":"Potential use of polyethyleneglycol conjugated recombinant IL-2 in common variable immunodeficiency","volume":"4","author":"Cunningham-Rundles","year":"1993","journal-title":"Immunodeficiency"},{"key":"2022011518425244300_b37","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1056\/NEJM199410063311405","article-title":"Brief report: enhanced humoral immunity in common variable immunodeficiency after long-term treatment with polyethyleneglycol conjugated interleukin-2","volume":"331","author":"Cunningham-Rundles","year":"1994","journal-title":"N Engl J Med"},{"key":"2022011518425244300_b38","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1365-3083.1994.tb03352.x","article-title":"Ligation of leucocyte function-associated (LFA) molecule-1 provides an accessory signal for T-cell activation with pokeweed mitogen","volume":"39","author":"Wallays","year":"1994","journal-title":"Scand J Immunol"},{"key":"2022011518425244300_b39","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/BF00917124","article-title":"Clinical and immunologic analyses of 103 patients with common variable immunodeficiency","volume":"9","author":"Cunningham-Rundles","year":"1989","journal-title":"J Clin Immunol"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2249.1997.tb08313.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2249.1997.tb08313.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/110\/2\/167\/42205755\/j.1365-2249.1997.tb08313.x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/110\/2\/167\/42205755\/j.1365-2249.1997.tb08313.x.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,15]],"date-time":"2022-01-15T18:43:19Z","timestamp":1642272199000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/110\/2\/167\/6483354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,11]]},"references-count":39,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2007,7,27]]},"published-print":{"date-parts":[[2007,7,27]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2249.1997.tb08313.x","relation":{},"ISSN":["0009-9104","1365-2249"],"issn-type":[{"value":"0009-9104","type":"print"},{"value":"1365-2249","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[1997,11]]},"published":{"date-parts":[[1997,11]]}}}